Davita - Oklahoma City South is a medicare approved dialysis facility center in Oklahoma City, Oklahoma and it has 16 dialysis stations. It is located in Oklahoma county at 319 Sw 59th Street, Oklahoma City, OK, 73109. You can reach out to the office of Davita - Oklahoma City South at (405) 634-3708. This dialysis clinic is managed and/or owned by Davita. Davita - Oklahoma City South has the following ownership type - Profit. It was first certified by medicare in August, 1992. The medicare id for this facility is 372518 and it accepts patients under medicare ESRD program.
| Name | Davita - Oklahoma City South |
|---|---|
| Location | 319 Sw 59th Street, Oklahoma City, Oklahoma |
| No. of Dialysis Stations | 16 |
| Medicare ID | 372518 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 319 Sw 59th Street, Oklahoma City, Oklahoma, 73109 | |
| (405) 634-3708 | |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
| NPI Number | 1124080486 |
| Organization Name | Oklahoma City South Dialysis |
| Doing Business As | Dva Healthcare Renal Care Inc |
| Address | 319 Sw 59th St Oklahoma City, Oklahoma, 73109 |
| Phone Number | (405) 634-3708 |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 18 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 81 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 375 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Oklahoma City South with elevated calcium levels.
| Patients with hypercalcemia | 81 |
| Hypercalcemia patient months | 375 |
| Patients with Serumphosphor | 85 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
| Patients with Serumphosphor greater than 7 mg/dL | 25 |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 105 |
| Patient months included in arterial venous fistula and catheter summaries | 389 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 72 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 13 |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 32 |
| Hospitalization Rate in facility | 109.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 267.2 |
| Hospitalization Rate: Lower Confidence Limit | 48.4 |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Oklahoma City South were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 16.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 41.2 |
| Readmission Rate: Lower Confidence Limit | 4 |
News Archive
The National Headache Foundation is pleased to announce that Alexander Feoktistov, M.D., Ph.D., Director of Research at Diamond Headache Clinic, Chicago, Illinois, has been named the recipient of the 2015 NHF Lectureship. As the premier educational and informational resource for those living with headache disorders, their family members, physicians, allied health professionals, and health policy decision makers, the NHF created this award to preserve the highest level of neurobiological research and advancement in medicine today.
WHO and HRP launch the Labour Care Guide to improve every woman's experience of childbirth, and to help ensure the health and well-being of women and their babies.
Vertex Pharmaceuticals Incorporated today announced plans to enroll an additional treatment arm as part of its ongoing Phase 2 clinical trial evaluating 12-week regimens of Vertex's lead investigational hepatitis C virus (HCV) protease inhibitor, telaprevir, in combination with its lead investigational HCV polymerase inhibitor, VX-222.
In their quest for new agents, pharmaceutical researchers test millions of substances all over the world. They like using color-forming reactions to identify new molecules. However, in intensively colored solutions or in the case of mixtures with multiple substances these tests fail.
› Verified 5 days ago